Impact of zilebesiran, an investigational RNA interference therapeutic targeting hepatic angiotensinogen, on renin-angiotensin system biomarkers in patients with mild-to-moderate hypertension
Event: ESC Congress 2025
Topic: Pharmacotherapy
Session: Treatment of hypertension: randomised controlled trials
